Repare Therapeutics

Repare is a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

[Repare Therapeutics @RepareRx]

Today, we announced our second quarter 2025 financial results and provided a business and clinical update. Full press release with additional details: https://t.co/6vCttk1tUu

[Repare Therapeutics @RepareRx]

We are excited to announce an exclusive worldwide licensing agreement with @DebiopharmNews, building on our successful collaboration to develop lunresertib and Debio 0123. Read our press release for more details: https://t.co/qoH7QyebOL #PKMYT1 #WEE1 #precisiononcology

[Repare Therapeutics @RepareRx]

Our research paper on the discovery of RP-1664, our first-in-class, highly selective, oral PLK4 inhibitor, has been published in the Journal of Medicinal Chemistry! Read the article here: https://t.co/04TzT0p5Mo #precisiononcology #cancerresearch #PLK4

[Repare Therapeutics @RepareRx]

Today, we announced our first quarter 2025 financial results and provided a business and clinical update. Full press release with additional details: https://t.co/sBwwAPj3lU

[Repare Therapeutics @RepareRx]

We’re headed to Chicago! Repare is pleased to announce that we will present two mini-oral and four poster presentations during hashtag#AACR25. Read our press release for more details: https://t.co/U74IG0aIuo #precisiononcology #syntheticlethality #cancerresearch

[Repare Therapeutics @RepareRx]

We are pleased to share that our research exploring lunresertib+camonsertib in CCNE1 amplified #ovarian and #endometrial orthotopic PDX models has been published in @NatureMedicine. Read the study here: https://t.co/mZ3miztIsj #precisiononcology

[Repare Therapeutics @RepareRx]

We are delighted to share the latest publication on our PLK4 program, we are proud of our researchers and hopeful that this drug will provide benefit for pediatric patients. https://t.co/5UCwxZOxiH
#pediatriccancer #PLK4 #neuroblastoma

[Repare Therapeutics @RepareRx]

Exciting update! Today we announced positive results of the lunresertib and camonsertib combination from the MYTHIC Phase 1 gynecologic expansion clinical trial. Join our webcast at 4:30 pm ET. Learn more here: https://t.co/ObSCO7T9hm

[Repare Therapeutics @RepareRx]

Today, we announced our third quarter 2024 financial results and provided a business and clinical update. Full press release with additional details: https://t.co/GPZXgPs3fF $RPTX

[Repare Therapeutics @RepareRx]

We look forward to sharing efficacy data from the gynecological cancer expansion cohort of MYTHIC in December 2024! #precisiononcology

[Repare Therapeutics @RepareRx]

We announced updated positive safety and tolerability results from the Phase 1 MYTHIC clinical trial at #ENA2024. This analysis demonstrates a successful approach to mitigating mechanism-based anemia while maintaining clinical benefit in patients. https://t.co/KMWvZ1wISA

[Repare Therapeutics @RepareRx]

Inviting all attendees of the 36th EORTC-NCI-AACR Symposium at the CCIB in Barcelona to join Dr. Martin Højgaard and @RepareRx for a presentation on the impact of individualised schedule optimisation in our Phase 1 MYTHIC Study. See you at #ENA2024!

[Repare Therapeutics @RepareRx]

Join Repare's Director of Bioinformatics, Ian Silverman, at the 36th @EORTC - @theNCI - @AACR Symposium on Molecular Targets and Cancer Therapeutics next week when he will speak about the importance of #bioinformatics to patient trial matching. #precisiononcology

[Repare Therapeutics @RepareRx]

This combination is designed to meaningfully improve patient outcomes by mitigating PARP inhibitor resistance, an area of high unmet medical need. Learn more here: https://t.co/il0PI76w5s #precisiononcology

[Repare Therapeutics @RepareRx]

We are one step closer to potentially improving the lives of patients with the first patient dosed with RP-3467, our potential best-in-class Polθ ATPase inhibitor by demonstrating complete and durable tumor regressions in combination with olaparib with no additive toxicities.

[Repare Therapeutics @RepareRx]

Thank you to investigators at @MSKCancerCenter for presenting results of our collaboration at @ASTRO_org's annual meeting highlighting encouraging responses for camonsertib with #radiotherapy: https://t.co/yS0geOtYn2

[Repare Therapeutics @RepareRx]

We presented new data at @AACR's 15th Annual Ovarian Cancer Research Symposium in Seattle highlighting the impact and inherent chemotherapy resistance of alterations in CCNE1, FBXW7, and PPP2R1A in patients with metastatic ovarian and endometrial cancers. https://t.co/kyETFoYAjp

[Repare Therapeutics @RepareRx]

Join us Saturday September at ESMO - European Society for Medical Oncology where we will share new data from Module 1 of our ongoing Phase 1/2 TRESR clinical trial. Learn more here: https://t.co/CUl3Zvh7Lf

#precisiononcology #syntheticlethality #clinicaltrials

[Repare Therapeutics @RepareRx]

Join @RepareRx at the @HCWCO 26th Annual Global Investment Conference this week for a company presentation. Click here to join the webcast: https://t.co/wPbSnKKhFm $RPTX

[Repare Therapeutics @RepareRx]

Tune in with @RepareRx's management team in a fireside chat at the @MorganStanley Annual Global Healthcare Conference in NYC today. We look forward to connecting in person! Click here to watch the webcast: https://t.co/bqiQsGGPKm $RPTX #precisiononcology #syntheticlethality